Heart failure therapy in diabetic patients-comparison with the recent ESC/EASD guideline
<p>Abstract</p> <p>Background</p> <p>To assess heart failure therapies in diabetic patients with preserved as compared to impaired systolic ventricular function.</p> <p>Methods</p> <p>3304 patients with heart failure from 9 different studies were...
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2011-02-01
|
| Series: | Cardiovascular Diabetology |
| Online Access: | http://www.cardiab.com/content/10/1/15 |
| _version_ | 1818525079730913280 |
|---|---|
| author | Angermann Christiane E Lüers Claus Neumann Till Stahrenberg Raoul Richter Annette Störk Stefan Düngen Hans-Dirk Wachter Rolf Edelmann Frank Mehrhof Felix Gelbrich Götz Pieske Burkert |
| author_facet | Angermann Christiane E Lüers Claus Neumann Till Stahrenberg Raoul Richter Annette Störk Stefan Düngen Hans-Dirk Wachter Rolf Edelmann Frank Mehrhof Felix Gelbrich Götz Pieske Burkert |
| author_sort | Angermann Christiane E |
| collection | DOAJ |
| description | <p>Abstract</p> <p>Background</p> <p>To assess heart failure therapies in diabetic patients with preserved as compared to impaired systolic ventricular function.</p> <p>Methods</p> <p>3304 patients with heart failure from 9 different studies were included (mean age 63 ± 14 years); out of these, 711 subjects had preserved left ventricular ejection fraction (≥ 50%) and 994 patients in the whole cohort suffered from diabetes.</p> <p>Results</p> <p>The majority (>90%) of heart failure patients with reduced ejection fraction (SHF) and diabetes were treated with an ACE inhibitor (ACEi) or angiotensin receptor blocker (ARB) or with beta-blockers. By contrast, patients with diabetes and preserved ejection fraction (HFNEF) were less likely to receive these substance classes (p < 0.001) and had a worse blood pressure control (p < 0.001). In comparison to patients without diabetes, the probability to receive these therapies was increased in diabetic HFNEF patients (p < 0.001), but not in diabetic SHF patients. Aldosterone receptor blockers were given more often to diabetic patients with reduced ejection fraction (p < 0.001), and the presence and severity of diabetes decreased the probability to receive this substance class, irrespective of renal function.</p> <p>Conclusions</p> <p>Diabetic patients with HFNEF received less heart failure medication and showed a poorer control of blood pressure as compared to diabetic patients with SHF. SHF patients with diabetes were less likely to receive aldosterone receptor blocker therapy, irrespective of renal function.</p> |
| first_indexed | 2024-12-11T06:04:57Z |
| format | Article |
| id | doaj.art-31e5974ca0514e6c8da2a71018a3361d |
| institution | Directory Open Access Journal |
| issn | 1475-2840 |
| language | English |
| last_indexed | 2024-12-11T06:04:57Z |
| publishDate | 2011-02-01 |
| publisher | BMC |
| record_format | Article |
| series | Cardiovascular Diabetology |
| spelling | doaj.art-31e5974ca0514e6c8da2a71018a3361d2022-12-22T01:18:20ZengBMCCardiovascular Diabetology1475-28402011-02-011011510.1186/1475-2840-10-15Heart failure therapy in diabetic patients-comparison with the recent ESC/EASD guidelineAngermann Christiane ELüers ClausNeumann TillStahrenberg RaoulRichter AnnetteStörk StefanDüngen Hans-DirkWachter RolfEdelmann FrankMehrhof FelixGelbrich GötzPieske Burkert<p>Abstract</p> <p>Background</p> <p>To assess heart failure therapies in diabetic patients with preserved as compared to impaired systolic ventricular function.</p> <p>Methods</p> <p>3304 patients with heart failure from 9 different studies were included (mean age 63 ± 14 years); out of these, 711 subjects had preserved left ventricular ejection fraction (≥ 50%) and 994 patients in the whole cohort suffered from diabetes.</p> <p>Results</p> <p>The majority (>90%) of heart failure patients with reduced ejection fraction (SHF) and diabetes were treated with an ACE inhibitor (ACEi) or angiotensin receptor blocker (ARB) or with beta-blockers. By contrast, patients with diabetes and preserved ejection fraction (HFNEF) were less likely to receive these substance classes (p < 0.001) and had a worse blood pressure control (p < 0.001). In comparison to patients without diabetes, the probability to receive these therapies was increased in diabetic HFNEF patients (p < 0.001), but not in diabetic SHF patients. Aldosterone receptor blockers were given more often to diabetic patients with reduced ejection fraction (p < 0.001), and the presence and severity of diabetes decreased the probability to receive this substance class, irrespective of renal function.</p> <p>Conclusions</p> <p>Diabetic patients with HFNEF received less heart failure medication and showed a poorer control of blood pressure as compared to diabetic patients with SHF. SHF patients with diabetes were less likely to receive aldosterone receptor blocker therapy, irrespective of renal function.</p>http://www.cardiab.com/content/10/1/15 |
| spellingShingle | Angermann Christiane E Lüers Claus Neumann Till Stahrenberg Raoul Richter Annette Störk Stefan Düngen Hans-Dirk Wachter Rolf Edelmann Frank Mehrhof Felix Gelbrich Götz Pieske Burkert Heart failure therapy in diabetic patients-comparison with the recent ESC/EASD guideline Cardiovascular Diabetology |
| title | Heart failure therapy in diabetic patients-comparison with the recent ESC/EASD guideline |
| title_full | Heart failure therapy in diabetic patients-comparison with the recent ESC/EASD guideline |
| title_fullStr | Heart failure therapy in diabetic patients-comparison with the recent ESC/EASD guideline |
| title_full_unstemmed | Heart failure therapy in diabetic patients-comparison with the recent ESC/EASD guideline |
| title_short | Heart failure therapy in diabetic patients-comparison with the recent ESC/EASD guideline |
| title_sort | heart failure therapy in diabetic patients comparison with the recent esc easd guideline |
| url | http://www.cardiab.com/content/10/1/15 |
| work_keys_str_mv | AT angermannchristianee heartfailuretherapyindiabeticpatientscomparisonwiththerecentesceasdguideline AT luersclaus heartfailuretherapyindiabeticpatientscomparisonwiththerecentesceasdguideline AT neumanntill heartfailuretherapyindiabeticpatientscomparisonwiththerecentesceasdguideline AT stahrenbergraoul heartfailuretherapyindiabeticpatientscomparisonwiththerecentesceasdguideline AT richterannette heartfailuretherapyindiabeticpatientscomparisonwiththerecentesceasdguideline AT storkstefan heartfailuretherapyindiabeticpatientscomparisonwiththerecentesceasdguideline AT dungenhansdirk heartfailuretherapyindiabeticpatientscomparisonwiththerecentesceasdguideline AT wachterrolf heartfailuretherapyindiabeticpatientscomparisonwiththerecentesceasdguideline AT edelmannfrank heartfailuretherapyindiabeticpatientscomparisonwiththerecentesceasdguideline AT mehrhoffelix heartfailuretherapyindiabeticpatientscomparisonwiththerecentesceasdguideline AT gelbrichgotz heartfailuretherapyindiabeticpatientscomparisonwiththerecentesceasdguideline AT pieskeburkert heartfailuretherapyindiabeticpatientscomparisonwiththerecentesceasdguideline |